

Curidium Medica plc ("Curidium" or the "Company")

Curidium Announces Directors' Purchase of Company Shares

LONDON, UK, 29th January, 2008, Curidium Medica plc, (LSE:CUR), a personalized medicine company focused on bringing the right drug to the right patient, announced today that directors Gosse B. Bruinsma M.D., Chairman, and Rob Smith, Finance Director, each today have purchased 200,000 ordinary shares in the Company at a price of 2.55 pence per share.

Following these transactions, Gosse Bruinsma is now interested in 200,000 ordinary shares, representing approximately 0.035 per cent of the Company's total issued share capital and Rob Smith is also interested in 200,000 shares, representing approximately 0.035 per cent of the Company's total issued share capital.

END

For further information please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Charlie Cunningham +44 (0) 20 7600 1658
JM Finn Capital Markets Ltd

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics

About Curidium Medica, plc (Curidium)

Curidium is a personalized medicine company developing companion diagnostics and targeted medicines to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous with patient populations consisting of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium intends to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: www.curidium.com.